We have achieved a major milestone, securing a Day-1 launch for generic Apremilast across the EU.
Indicated for the treatment of psoriatic arthritis and moderate-to-severe plaque psoriasis, our generic version is a high-quality alternative to the reference brand, Otezla®.
“Adalvo is honored to serve its esteemed partners with this Day-1 launch. We are excited to bring this affordable, first and only oral psoriasis treatment to patients around the world.”
Interested in adding Apremilast to your portfolio? Contact our team today to discuss this and to see our full dermatology range.
Backed by a robust development program, and a highly competitive cost-of-goods profile, our generic Apremilast offers an attractive value proposition for both healthcare systems and commercial partners.
Accelerating global demand
IQVIA figures show worldwide sales for Apremilast reached $4.76 billion in the 12 months to June 2025. A two-year CAGR of 8% reflects continued growth and sustained clinical relevance for this molecule.
Marketing authorizations have already been granted in several key EU markets, and we have further opportunities available for partners looking for a fast-to-market launch.
This milestone further strengthens Adalvo’s specialized dermatology and rheumatology portfolio and reflects our ongoing commitment to expanding access to high-value treatments for both patients and partners.
Contact us to learn more and to see our complete dermatology portfolio.